TransMedics Group Investor Presentation — May 2019

Document content

2DBD DonorsCautionary Note Regarding Forward -Looking Statements

This presentation contains forward -looking statements .Investors arecautioned nottoplace undue reliance onthese forward -looking statements, including

statements about our results ofoperations, commercial opportunity and therate ofadoption and benefits oftheOCS.Each forward -looking statement is

subject torisks and uncertainties that could cause actual results todiffer materially from those expressed orimplied insuch statement .Applicable risks and

uncertainties include those related toouranticipation that wewillcontinue toincur losses inthefuture ;ourpotential need toraise additional funding ;our

existing and anyfuture indebtedness, including ourability tocomply with affirmative and negative covenants under ourcredit agreement, and ourability to

obtain additional financing onfavorable terms oratall;thefluctuation ofourfinancial results from quarter toquarter ;ourability tousenetoperating losses

and research and development credit carryforwards ;ourdependence onthesuccess oftheOCS;therate and degree ofmarket acceptance oftheOCS;our

ability toeducate patients, surgeons, transplant centers and private payors ofbenefits offered bythe OCS;our ability toimprove theOCS platform ;our

dependence onalimited number ofcustomers forasignificant portion ofournetrevenue ;thetiming ofand ourability toobtain and maintain regulatory

approvals orclearances forourOCS products ;ourability toadequately respond toFDA follow -upinquiries inatimely manner ;theperformance ofourthird -

party suppliers and manufacturers ;thetiming orresults ofclinical trials fortheOCS;our manufacturing, sales, marketing and clinical support capabilities

and strategy ;attacks against ourinformation technology infrastructure ;theeconomic, political and other risks associated with ourforeign operations ;our

ability toattract and retain keypersonnel ;ourability toprotect, defend, maintain and enforce ourintellectual property rights relating totheOCS and avoid

allegations that ourproducts infringe, misappropriate orotherwise violate theintellectual property rights ofthird parties ;ourexpectations forthepricing of

the OCS, aswell asthe reimbursement coverage forthe OCS inthe United States and internationally ;regulatory developments inthe United States,

European Union and other jurisdictions ;theextent and success ofcompeting products that areormay become available ;theimpact ofany product recalls

orimproper useofourproducts ;ourestimates regarding revenues, expenses and needs foradditional financing ;and therisks identified under theheading

“Risk Factors” and elsewhere inthefinal prospectus dated May 1,2019 related toourinitial public offering, and inourquarterly report onForm 10-Qforthe